Jaguar Health Inc (NASDAQ: JAGX)’s stock price has decreased by -12.82 compared to its previous closing price of 0.55. However, the company has seen a -16.40% decrease in its stock price over the last five trading sessions. accessnewswire.com reported 2025-02-27 that Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease FDA meeting expected in Q2 2025 on the statistically significant results of the Phase 3 OnTarget trial of crofelemer in the prespecified subgroup of patients with breast cancer Jaguar has received an indication of interest to acquire the Company SAN FRANCISCO, CA / ACCESS Newswire / February 27, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) today announced that its Board of Directors (the “Board”) has adopted a limited duration stockholder rights plan (the “Rights Plan”). “Jaguar, which, like many other biotechnology companies, continues to experience a significant and ongoing dislocation in the trading price of its common stock, has received an indication of interest to acquire the Company.
Is It Worth Investing in Jaguar Health Inc (NASDAQ: JAGX) Right Now?
Moreover, the 36-month beta value for JAGX is 0.82. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for JAGX is 12.52M and currently, short sellers hold a 5.09% of that float. On March 12, 2025, JAGX’s average trading volume was 482.03K shares.
JAGX’s Market Performance
The stock of Jaguar Health Inc (JAGX) has seen a -16.40% decrease in the past week, with a -43.94% drop in the past month, and a -51.81% fall in the past quarter. The volatility ratio for the week is 9.95%, and the volatility levels for the past 30 days are at 10.57% for JAGX. The simple moving average for the last 20 days is -33.83% for JAGX stock, with a simple moving average of -71.21% for the last 200 days.
Analysts’ Opinion of JAGX
Many brokerage firms have already submitted their reports for JAGX stocks, with Cantor Fitzgerald repeating the rating for JAGX by listing it as a “Overweight.” The predicted price for JAGX in the upcoming period, according to Cantor Fitzgerald is $5 based on the research report published on July 07, 2021 of the previous year 2021.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see JAGX reach a price target of $2. The rating they have provided for JAGX stocks is “Buy” according to the report published on July 11th, 2017.
JAGX Trading at -44.16% from the 50-Day Moving Average
After a stumble in the market that brought JAGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.79% of loss for the given period.
Volatility was left at 10.57%, however, over the last 30 days, the volatility rate increased by 9.95%, as shares sank -41.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -53.74% lower at present.
During the last 5 trading sessions, JAGX fell by -16.40%, which changed the moving average for the period of 200-days by -94.43% in comparison to the 20-day moving average, which settled at $0.7201. In addition, Jaguar Health Inc saw -52.82% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for JAGX
Current profitability levels for the company are sitting at:
- -2.85 for the present operating margin
- 0.69 for the gross margin
The net margin for Jaguar Health Inc stands at -3.6. The total capital return value is set at -0.77. Equity return is now at value -432.40, with -72.69 for asset returns.
Based on Jaguar Health Inc (JAGX), the company’s capital structure generated 0.72 points at debt to capital in total, while cash flow to debt ratio is standing at -0.85. The debt to equity ratio resting at 2.52. The interest coverage ratio of the stock is -34.76.
Currently, EBITDA for the company is -33.13 million with net debt to EBITDA at -0.7. When we switch over and look at the enterprise to sales, we see a ratio of 2.75. The receivables turnover for the company is 8.02for trailing twelve months and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.84.
Conclusion
To wrap up, the performance of Jaguar Health Inc (JAGX) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
